Patents Assigned to Genomill Health Oy
  • Patent number: 11970736
    Abstract: The present disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the disclosed embodiments is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The disclosed embodiments includes two target-specific nucleic acid probes per genetic target, a barcode loop oligo and a bridge oligo or bridge oligo complex.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: April 30, 2024
    Assignee: Genomill Health Oy
    Inventors: Juha-Pekka Pursiheimo, Tatu Hirvonen, Anttoni Korkiakoski, Manu Tamminen
  • Publication number: 20240068010
    Abstract: The present invention disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the invention is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The invention includes at least target-specific nucleic acid probes per genetic target (first probe, second probe and target-specific probe) and a bridge oligo or bridge oligo complex.
    Type: Application
    Filed: August 31, 2022
    Publication date: February 29, 2024
    Applicant: Genomill Health Oy
    Inventors: Juha-Pekka Pursiheimo, Tatu Hirvonen, Anttoni Korkiakoski, Manu Tamminen
  • Publication number: 20240068022
    Abstract: The present invention disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the invention is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The invention includes two target-specific nucleic acid probes per genetic target, a barcode loop oligo and a bridge oligo or bridge oligo complex.
    Type: Application
    Filed: August 31, 2022
    Publication date: February 29, 2024
    Applicant: Genomill Health Oy
    Inventors: Juha-Pekka Pursiheimo, Tatu Hirvonen, Anttoni Korkiakoski, Manu Tamminen
  • Patent number: 11898202
    Abstract: The present invention disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the invention is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The invention includes one or more target-specific nucleic acid probes per genetic target and a bridge oligo or bridge oligo complex.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: February 13, 2024
    Assignee: Genomill Health Oy
    Inventors: Juha-Pekka Pursiheimo, Tatu Hirvonen, Manu Tamminen, Anttoni Korkiakoski
  • Patent number: 11486003
    Abstract: The present disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the present disclosure is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The disclosed embodiments includes one or more target-specific nucleic acid probes per genetic target (left probe and right probe) and a bridge oligo or bridge oligo complex.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: November 1, 2022
    Assignee: Genomill Health Oy
    Inventors: Juha-Pekka Pursiheimo, Tatu Hirvonen, Manu Tamminen, Anttoni Korkiakoski
  • Publication number: 20220298566
    Abstract: The present invention disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the invention is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The invention includes one or more target-specific nucleic acid probes per genetic target and a bridge oligo or bridge oligo complex.
    Type: Application
    Filed: March 3, 2022
    Publication date: September 22, 2022
    Applicant: Genomill Health Oy
    Inventors: Juha-Pekka Pursiheimo, Tatu Hirvonen, Manu Tamminen, Anttoni Korkiakoski
  • Publication number: 20220298569
    Abstract: The present disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the present disclosure is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The disclosed embodiments includes one or more target-specific nucleic acid probes per genetic target (left probe and right probe) and a bridge oligo or bridge oligo complex.
    Type: Application
    Filed: March 3, 2022
    Publication date: September 22, 2022
    Applicant: Genomill Health Oy
    Inventors: Juha-Pekka Pursiheimo, Tatu Hirvonen, Manu Tamminen, Anttoni Korkiakoski